title: The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa.
authors.affiliation: Department of Haematology, Alfred Health, 55 Commercial Road, Melbourne, Victoria, 3004, Australia, K.Htun@alfred.org.au.
authors.forename: K T
authors.initials: KT
authors.lastname: Htun
authors.forename: J
authors.initials: J
authors.lastname: McFadyen
authors.forename: H A
authors.initials: HA
authors.lastname: Tran
mesh_terms: D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000069604:Dabigatran; D004322:Drainage; D015942:Factor VIIa / Q000627:therapeutic use*; D016489:Head Injuries, Closed / Q000150:complications; D006408:Hematoma, Subdural / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology / Q000601:surgery; D008297:Male; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000627:therapeutic use; D013918:Thrombin Time; D014057:Tomography, X-Ray Computed; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D011994:Recombinant Proteins; D015091:beta-Alanine; C103587:recombinant FVIIa; D015942:Factor VIIa; D000069604:Dabigatran